The pharmacological management of obesity in Prader-Willi syndrome: what does the future hold? [0.03%]
普瑞德·威利综合征肥胖的药物治疗：未来之路何去何从？
Graziano Grugni,Alessandro Sartorio,Antonino Crinò et al.
Graziano Grugni et al.
Role of novel β-lactam antibiotics in the treatment of bacterial pneumonia [0.03%]
新型β-内酰胺类抗生素在细菌性肺炎治疗中的作用
Susanna Esposito,Nicola Principi
Susanna Esposito
Introduction: Bacterial pneumonia remains a leading cause of morbidity and mortality. β-lactam antibiotics have represented the backbone of treatment for community-acquired and hospital-acquired pneumonia. However, the e...
Wolfgang A Schmidt
Wolfgang A Schmidt
Introduction: Giant cell arteritis (GCA) is the most common primary vasculitis and is associated with substantial morbidity. Glucocorticoids play a central role in GCA, resulting in cumulative glucocorticoid exposures tha...
Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction [0.03%]
jak抑制剂初治骨髓纤维化患者联合治疗的证据、理论依据和临床方向
Laura Li Gagnon,Claire N Harrison
Laura Li Gagnon
Introduction: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, cytopenias, bone marrow fibrosis. Frontline therapy relies upon Janus kinase (JAK) inhibition...
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update [0.03%]
杜氏肌营养不良药物治疗的新进展
Leyken Wilson,Lucy M Johnson,Daniel J Berlau
Leyken Wilson
Introduction: Duchenne muscular dystrophy (DMD) is a severe X-linked disorder caused by mutations in the dystrophin gene, resulting in progressive skeletal muscle degeneration, loss of ambulation, and eventual cardiopulmo...
Clinical positioning and future prospects of JAK inhibitors in alopecia areata [0.03%]
JAK抑制剂治疗斑秃的临床定位及前景展望
Moyuka Wada-Irimada,Takehiro Takahashi,Yoshihide Asano
Moyuka Wada-Irimada
Introduction: Alopecia areata (AA) is a chronic autoimmune disease characterized by non-scarring hair loss driven by cytotoxic attack against anagen hair follicles. Janus kinase (JAK) inhibitors disrupt the pathogenic sig...
Evaluation of novel treatments for metastatic castration-resistant prostate cancer [0.03%]
新型转移性去势抵抗性前列腺癌治疗的评估
Gürkan Güner,Cagatay Arslan
Gürkan Güner
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with a median overall survival of approximately 2 years. Although major therapeutic advances have been achieved over the past ...
New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin [0.03%]
新型和目前正在研究的促血红素原卟啉症药物疗法：德西美 agon 和 Bitopertin 突出临床效果
Jasmin Barman-Aksözen,Francesca Granata,Sebastian Wäscher et al.
Jasmin Barman-Aksözen et al.
Introduction: The erythropoietic protoporphyrias (EPP) are ultra-rare inborn errors of the heme biosynthesis characterized by painful and debilitating phototoxic reactions in the blood vessels upon exposure to visible lig...
An evaluation of cytisinicline for smoking cessation in adult smokers [0.03%]
戒烟成年人吸烟者中药用植物半枫荷中生物碱戒烟的评估研究
Nancy A Rigotti,Neal L Benowitz
Nancy A Rigotti
Introduction: Cigarette smoking is the world's leading preventable cause of death. With no new smoking cessation pharmacotherapy approved since 2006, the 29 million US adults who smoke need new treatment options. Cytisini...
Persistence of fixed-dose combinations including dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes in Japan: analysis using a claims database [0.03%]
日本二肽基肽酶-4抑制剂复方制剂固定剂量在2型糖尿病患者中的用药持续性：来自理赔数据库的分析研究
Kohei Kaku,Yusuke Naito
Kohei Kaku
Background: Persistence with treatments for type 2 diabetes (T2D) is fundamental but may be suboptimal. Fixed-dose combination (FDC) treatment can help improve persistence with treatment, although current data are limited...